<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="716">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>29/09/2005</approvaldate>
  <actrnumber>ACTRN12605000558628</actrnumber>
  <trial_identification>
    <studytitle>A randomised, double-blind trial evaluating preoperative medical treatment of endometriosis prior to radical laparoscopic excision of disease</studytitle>
    <scientifictitle>A randomised, double-blind trial evaluating preoperative medical treatment of endometriosis prior to radical laparoscopic excision of disease  to observe the effect on their post-operative outcome with regard to symptomatology, change in quality of life and the ease of completing the procedure and time taken for the procedure.</scientifictitle>
    <utrn />
    <trialacronym>not applicable</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Endometriosis</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1. Three months of the continuous oral contraceptive pill + placebo GnRH analogue
2. Three months of GnRH analogue + placebo pill</interventions>
    <comparator>3. Three months of placebo pill + placebo GnRH analogu</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the effects of pre-treatment of women with endometriosis prior to radical laparoscopic excision of endometriosis compared to no treatment. Areas to be assessed include:
Effect on pain score as assessed by pain scores on a visual analogue scale</outcome>
      <timepoint>Measured at baseline, surgery date and then at three monthly intervals for a 12 month period post operatively.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effects of pre-treatment of women with endometriosis prior to radical laparoscopic excision of endometriosis compared to no treatment. Areas to be assessed include:
Pain assessment by change using the McGill pain questionnaire</outcome>
      <timepoint>Measured at baseline, surgery date and then at three monthly intervals for a 12 month period post operatively.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the effects of pre-treatment of women with endometriosis prior to radical laparoscopic excision of endometriosis compared to no treatment. Areas to be assessed include:
Quality of life change assessed by the AQOL, SF12 and sexual activity questionnaires</outcome>
      <timepoint>Measured at baseline, surgery date and then at three monthly intervals for a 12 month period post operatively.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To observe a difference in the clinical and quality of life outcomes if women are treated by the oral contraceptive pill, a GnRH analogue or placebo.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To observe any difference between groups at the time of surgery as regards to operative time, perceived surgical difficulty and blood loss.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To observe any difference in the post-operative analgesia requirements between groups.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To observe any difference in re-treatment or adjuvant treatment within one year of follow-up.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Women who are known to have or suspected to have endometriosis as a cause of their symptoms2. Women who are equally willing to comply with medication administration 3. Women who are able complete questionnaires relating to pain and quality of life4. Women who have histological confirmation of endometriosis at surgery5. Women with suspected endometriosis based on history, clinical examination and current or previous investigations including laparoscopic features of endometriosis would be eligible for entry to the study.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Women with a suspected diagnosis of gynaecological malignancy or its precursors2. Women with current or chronic pelvic inflammatory disease3. Women who are currently pregnant or not willing to use barrier contraception during  the pre-operative period 4. Women who have a contra-indication to the use of oestrogens such as previous thrombo-embolic disease 5. Women who currently smoke and are over the age of 35 6. Women who have had a  previous reaction, or contra-indication  to the use of a GnRH analogue7. Women unable to give informed consent8. Women unable or unwilling to attend for a twelve month follow up visit.Note: Previous treatment for endometriosis is NOT an exclusion to trial participation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealment will be achieved by opening an opaque consecutively numbered envelope with the study allocation number identified on the envelope.</concealment>
    <sequence>Randomisation will be by computer-generated blocks in balanced groups</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>not applicable</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>11/01/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Department of EndoGynaecology Royal Hospital for Women</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of EndoGynaecology Royal Hospital for Women</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will treat women with either one of two medications or placebo for three months prior to their surgery to observe the effect on their post-operative outcome with regard to symptomatology, change in quality of life and the ease of completing the procedure and time taken for the procedure.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Area and Illawarra Health Service, Eastern Division</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jason Abbott</name>
      <address>Royal Hospital for Women
Level 2
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93826557</phone>
      <fax>+61 2 93826244</fax>
      <email>abbott@sesahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Jason Abbott</name>
      <address>Department of Endogynaecology
Royal Hospital for Women
Level 2
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93826557</phone>
      <fax>+61 2 93826244</fax>
      <email>abbott@sesahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>